Drugs / HER-2/neu peptide vaccine
last change Jan 2001 re-read 2 minutes ago

HER-2/neu peptide vaccine

Vaccine

Developed for
breast cancer · lung cancer · ovarian cancer
Investigated by
University of Washington

Trials 1 · a red edge is where a trial was stopped

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00005023 Mar 1999 → Jan 2001 breast cancer, lung cancer, ovarian cancer University of Washington Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HER-2/neu peptide vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005023
Modality Vaccine “HER-2/neu peptide vaccineNCT00005023